DYOptions
Options Trader
Viking Therapeutics now has enough cash to finish its phase 3 trials, so it can hold out for a home-run acquisition offer, likely nothing below $200 a share after its positive maintenance trial. The offering added $547.8M, lifting cash to about $1B, enough for roughly 24 months at a bit over $40M of monthly burn, though phase 3 may burn faster, and possibly close to the NDA stage. Dilution of 9% from stock and 5% from converts will be worth it. x.com x.comÂ
Viking Therapeutics' convertible offering is a bullish signal, showing management is confident enough in the stock's future to use a structure that converts to equity at a premium. Small companies only get such deals after significant progress, and demand was very high, with $100 million more raised despite heavy dilution. The six-year notes priced at a 2% coupon, which confirms the signal. x.com x.com x.comÂ
Viking Therapeutics is a beaten-down stock with good news. It has great Phase 1 data and more capital, after a 33% decline from recent highs. x.com x.comÂ
Viking Therapeutics gets zero credit for what has long looked like a top obesity drug. In its VK2735 maintenance study, patients switched to less-frequent dosing, including monthly, kept up to about 97% of prior weight loss and reached about 22% total over 33 weeks, addressing the weight-regain concern. The results came a day after Novo Nordisk signaled bigger obesity M&A, reviving takeout speculation, yet no one has bought Viking. x.com x.com x.comÂ
A crowded obesity-drug market could leave Viking Therapeutics fighting for fewer patients at much lower prices. Viking's CEO said a potential launch is about two and a half years away; in three years, Viking could be just another competitor. Hepatitis C blockbusters from many companies once faced too few patients to treat, a warning for long-term holders. x.com x.com x.comÂ
Viking Therapeutics holds the most valuable obesity peptide real estate outside Eli Lilly, making it a $100 stock in plain sight. VK2735 keeps producing compelling injectable and oral data, with the oral candidate surprising many and looking more competitive than Novo's oral program. Big Pharma badly needs differentiated obesity assets and Viking is one of few quality independents left, so a buyout would be no surprise and a bidding war could send it to $100+ fast. Alone it is a 3-5x story. … Show more
Viking Therapeutics' large short position sets up a squeeze, since great news would leave those shorts in big trouble. The daily chart shows a bullish ascending triangle. x.comÂ
Viking Therapeutics selling shares at $35 caps its upside; it should accept a buyout at double that price instead. It priced 7.85 million shares at $35 alongside $225 million of 2% convertible notes due 2032, after upsizing both offerings from $200 million. x.comÂ
Moderna's cash burn and persistent operating losses make profitable commercialization the central constraint despite promising melanoma results. Its revenue remains too small and uneven to cover development costs, while rising diluted shares weaken financial resilience. x.comÂ
Zura Bio's small target markets and cash-consuming clinical development make its binary risk not worth taking. Its nearest-term phase 2 programs target hidradenitis and systemic sclerosis; neither has a large addressable market. Phase 2, phase 3 and a biologics license application mean no revenue for five years or more, draining cash, leaving a high debt-to-margin ratio and causing dilution. x.comÂ
Viking Therapeutics is just another GLP-1 drug in a sea of many and will get crushed commercially by the big drugmakers. In a biotech bubble, only companies with a broad, diverse pipeline of potential blockbusters are worth owning. x.comÂ
Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.comÂ
